Advanced Filters
noise

rectal-disorders Clinical Trials

A listing of rectal-disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 697 clinical trials
H Helle Gangelhof, RN

Prospective Study of Extended Robotic Right Hemicolectomy With Complete Mesocolic Excision for Cancer

A single-center prospective study to elucidate whether extended robot-assisted right colectomy (e-RARC) performs as well as extended open right colectomy (e-ORC) in terms of specimen quality, and in addition, whether less postoperative morbidity and shorter length of stay (LOS) can be attained. Patients with colonic cancer near the right flexure …

18 years of age All Phase N/A
Y Yanghong Deng, PhD

Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer

Neoadjuvant chemoradiotherapy (CRT) followed by total mesenteric excision (TME) and adjuvant chemotherapy was the standard of treatment for locally advanced rectal cancer (LARC) in the past two decades. The main obstacles for improving survival benefit of LARC was distant metastasis. Recently, total neoadjuvant therapy (TNT) had been recommended as new …

18 - 70 years of age All Phase 2
J Junzhong lin, PhD

Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance

Colorectal cancer (CRC) is a common cancer that threatens human health, with the incidence ranking the third in the world. 70% of patients are in the middle and late stages whendiagnosed, and even after radical surgery, 30% - 50% of patients with CRC have recurrence or metastasis after radical surgery. …

18 - 80 years of age All Phase N/A
L Luigi Tortola, PhD

Metronidazole as Preoperative Therapy in CRC / FusoMetro-001

The proposed proof-of concept trial aims at determining the effectiveness of metronidazole in decreasing the Fusobacterium nucleatum load in tissues and possibly on its detrimental effects on tumor cells and tumor microenvironment.

18 years of age All Phase 2
S Sherief Abd-elsalam, lecturer

Mebendazole as Adjuvant Treatment for Colon Cancer

mebendazole treating colon cancer

18 years of age All Phase 3
R R Graham

Pelvic Health Electrically Evoked Recording (PEER) 2 Study

To collect physiological signals at several timepoints during the therapy evaluation period.

18 years of age All Phase N/A
J Jun Huang, MD

Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC

At present, radical resection ± preoperative neoadjuvant chemotherapy for colorectal cancer is still the standard comprehensive treatment. In recent years, immunotherapy of PD-1 monoclonal antibody has a significant effect in the second-line/first-line treatment of dMMR/MSI-H advanced colorectal cancer and the neoadjuvant treatment of early colorectal cancer. Synchronous multiple primary colorectal …

18 - 80 years of age All Phase 2
T Toni Seppala, Prof

Systemic Neoadjuvant and Adjuvant Control by Precision Medicine in Rectal Cancer

Rectal cancer represents the most complex area of multidisciplinary treatment in bowel surgery. In 2017, there were 1221 new rectal cancers in Finland. The prognosis of colorectal cancer (CRC) patients these days is almost exclusively driven by the occurrence of the metastatic form of the disease. The treatment of rectal …

18 - 100 years of age All Phase N/A
M Mikhail Fedianin, phD

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

Patients meeting the inclusion criteria will be randomized 1:1 into Cohort A (n ≈ 177) or Cohort BC (n ≈ 177). Cohort A is the control: patients receive combination chemotherapy with FOLFOX plus anti-EGFR therapy (panitumumab or cetuximab) based on RAS/BRAF wild-type data, according to clinical guidelines. The BC cohort …

18 - 99 years of age All Phase 3
M MILOU Fabrice, Dr

COLON-IM : Microbiota and Immune Infiltrate in Normal, Dysplastic and Neoplastic Colorectal Tissue

The primary objective of COLON-IM is to describe colorectal tissue microenvironment (neutrophils infiltrate) of patients with benign or malignant colorectal lesion (from stage I to III according to Tumor Node Metastasis (TNM)/ Union for International Cancer Control (UICC) classification).

18 years of age All Phase N/A

Simplify language using AI